If You Invested in Qualigen Therapeutics Inc (QLGN)

Qualigen Therapeutics, Inc. (NASDAQ: QLGN), now renamed AIxCrypto Holdings, Inc. with the trading symbol AIXC, has undergone a significant strategic transformation. According to its SEC filings, the company historically operated as an early-clinical-stage therapeutics business focused on developing treatments for adult and pediatric cancers. Its therapeutic portfolio has included the small-molecule program QN-302, a G-quadruplex-selective transcription inhibitor in a Phase 1a clinical trial, and a preclinical Pan-RAS program targeting RAS oncogene protein-protein interactions.

As described in the company’s registration statement on Form S-1 and multiple press releases, the business has expanded beyond traditional biotechnology into a technology- and Web3-focused model under the AIxCrypto brand. The company has established a C10 Cryptocurrency Asset Treasury (C10 Treasury), which applies an 80% passive and 20% active allocation strategy to a market-cap-weighted basket of the top 10 cryptocurrencies (excluding stablecoins). The passive component is designed to closely track a C10 index, while the active component is based on quantitative analysis and is expected to incorporate hedging tools such as stablecoins, options, and structured products.

In addition to treasury operations, the company has outlined a broader Web3 and crypto asset roadmap. Public communications describe initiatives around a BesTrade DeAI Agent, characterized as an AI-powered crypto trading agent intended to function as a meta exchange that connects users and value by optimizing transaction pathways and returns. The company has also referenced work on C10 Index products, a potential C10 ETF, and ecosystem tokens, including a potential C10 stablecoin and an EAI + Crypto RWA (Real World Asset) dual-bridge product, all framed as components of a Web3 ecosystem and digital asset infrastructure.

Corporate governance and capital structure have shifted alongside this business evolution. Through a private investment in public equity (PIPE) transaction described in a series of Form 8-K filings, Faraday Future Intelligent Electric Inc. agreed to invest in QLGN common and preferred stock, with the structure designed to give Faraday Future and affiliated investors majority beneficial ownership of the company’s common stock upon completion and stockholder approval. The PIPE included newly created Series B Convertible Preferred Stock, voting rights on an as-converted basis, and registration rights for resale of common shares underlying the preferred stock.

Following stockholder approval at a special meeting, the company implemented governance changes, including the appointment of new directors and executive officers associated with Faraday Future. SEC filings note that Faraday Future obtained rights to nominate a significant portion of the board, and that senior roles such as Co-Chief Executive Officer and Chief Financial Officer were filled by individuals who also hold leadership positions at Faraday Future. Nasdaq correspondence referenced in an 8-K filing indicates that these changes, together with the PIPE financing, were treated as a change-of-control transaction for purposes of Nasdaq Listing Rule 5635(b), with the company subsequently regaining compliance after obtaining majority stockholder approval.

The company’s rebranding to AIxCrypto Holdings, Inc. and the shift from a purely clinical-stage biotech profile to a cross-disciplinary enterprise focused on decentralized AI (DeAI), Web3 asset infrastructure, and intelligent trading systems are documented in press releases and Form 8-K disclosures. These communications describe a planned ecosystem architecture and multi-year development roadmap intended to position AIxCrypto as a gateway to the AI × Web3 era, while also noting that one early-clinical-stage therapeutic program (QN-302) and one preclinical Pan-RAS program remain part of the company’s business.

Investors researching the historical QLGN ticker should be aware that, as disclosed in SEC filings, the corporate name has been changed to AIxCrypto Holdings, Inc. and the Nasdaq symbol to AIXC. The company continues to be listed on The Nasdaq Capital Market, with filings detailing its efforts to comply with Nasdaq’s stockholder equity and shareholder approval rules, including private placements of preferred stock and related capital-raising activities.

Business segments and activities

• Therapeutics programs: QN-302, an investigational small molecule G-quadruplex-selective transcription inhibitor in a Phase 1a clinical trial; and a preclinical Pan-RAS small-molecule program targeting RAS oncogene protein-protein interaction.
• Digital asset treasury operations: C10 Treasury, which applies an 80% passive / 20% active allocation framework to top-10 cryptocurrencies by market capitalization, with infrastructure including cash settlement, bank accounts, and cryptocurrency custody accounts.
• AI and Web3 initiatives: BesTrade DeAI Agent, C10 Index and C10 Treasury products, potential C10 ETF, potential C10 stablecoin, and EAI + Crypto RWA dual-bridge products, all described in company news as engines of a broader crypto and Web3 ecosystem.
• Strategic partnerships and agreements: A co-development agreement with Marizyme, Inc. related to the DuraGraft vascular conduit solution, under which the company has provided funding and may receive payments in the nature of royalties on defined net sales, subject to specified caps and conditions.

Regulatory and listing context

Nasdaq communications disclosed in Form 8-K filings show that the company has addressed multiple listing-related issues, including stockholder equity requirements under Nasdaq Rule 5550(b)(1) and shareholder approval requirements under Nasdaq Rule 5635. The company has used private placements of preferred stock and strategic financings to support its equity position and to fund both its legacy therapeutic programs and its newer crypto-focused initiatives. A Panel Monitor period under Nasdaq rules is also noted, during which future compliance with equity requirements remains under review.

Overall, QLGN’s evolution into AIxCrypto Holdings, Inc. combines a legacy of clinical-stage oncology and infectious disease research with a new emphasis on digital assets, AI-driven trading, and Web3 infrastructure, as reflected in its SEC filings and public announcements.